ioflupane i-123 Report issue

Small molecule Imaging Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Ioflupane I-123 (trade name DaTscan) is a radioiodinated cocaine analogue synthesized from a key starting material Sn FP-CT via oxidative iododestannylation with sodium (123I)-iodide. Ioflupane I-123 binds reversibly with high affinity to the dopamine transporter (DaT) protein, a marker for presynaptic terminals in dopaminergic nigrostriatal neurons. It has been developed as a dopamine transporter imaging agent for single photon emission computed tomography (SPECT) which is claimed to be sensitive enough to differentiate changes in the nigrostriatal dopaminergic system in patients with Parkinsonism and healthy controls. DaTSCAN is unable to discriminate between Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. DaTscan is an adjunct to other diagnostic evaluations. Headache, nausea, vertigo, dry mouth, or dizziness of mild to moderate severity as well as hypersensitivity reactions and injection-site pain have been reported. The DaTscan injection may contain up to 6% of free iodide (iodine 123 or I-123). To decrease thyroid accumulation of I-123, the thyroid gland has to be blocked at least one hour before administration of DaTscan because of the long-term risk for thyroid neoplasia. DaTscan was first approved in the European Union (EU) on July 27, 2000. It is also approved in Israel, Switzerland and in the United States (a total of 33 countries).   NCATS

Chemistry

  • SMILES: COC(=O)[C@H]1[C@@H](c2ccc(I)cc2)C[C@@H]2CC[C@H]1N2CCCF
  • InChIKey: HXWLAJVUJSVENX-HZMVEIRTSA-N
  • Mol. Mass: 431.29
  • ALogP: 3.76
  • ChEMBL Molecules:
    ioflupane  
    None  
    ioflupane  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Imaging: 123-iodine
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$820.0500 - $1088.0500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

123i fp-cit | 123i-fp-cit | 123i-ioflupane | 12 i-fp-cit | (18f)fp-cit | 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane | beta-cit-fp | datscan | fluoropropylcarbomethoxyiodophenylnortropane | fpcit | fp-cit | i-123 ioflupane | i(123)-n-fluoropropyl-2-beta-carbomethoxy-3-(4-iodophenyl)nortropane | i(123)-n-omega-fluoropropyl-2-beta-carbomethoxy-3-beta(4-iodophenyl)nortropane | iodine ioflupane (123i) | ioflupane | ioflupane ((123)i) | ioflupane (123i) | ioflupane (123l) | ioflupane i123 | ioflupane i 123 | ioflupane i-123 | ioflupane i(123) | ioflupano (123i) | ioflupanum (123i) | l-123 ioflupane | n-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane | (o-methyl-11c)beta-cit-fp | v09ab03

Organizations (19)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Parkinsonian Disorders (approved 2011)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Alzheimer Disease (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 3)

Atrophy (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Cognitive Dysfunction (Phase 4)

Dementia (Phase 4)

Dementia, Vascular (Phase 3)

Essential Tremor (Phase 3)

Healthy Volunteers (Phase 1)

Lewy Body Disease (Phase 3)

Movement Disorders (Phase 4)

Pain (Phase 2)

Parkinson Disease (Phase 3)

Parkinsonian Disorders (Phase 4)

REM Sleep Behavior Disorder (Phase 4)

Supranuclear Palsy, Progressive (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue